Jason M. Broderick

Phase 3 data showed that the addition of the AKT inhibitor ipatasertib to standard therapy boosted radiographic progression-free survival in patients with advanced castration-resistant prostate cancer whose tumors had PTEN loss.

Following radical prostatectomy, circulating tumor cells may indicate an increased risk of recurrence earlier than a PSA rise.

The dual biomarker of ARID1A mutations and CXCL13 expression was associated with improved overall survival in patients with advanced urothelial carcinoma.

Anti–PD-1/PD-L1 agents were associated with similar efficacy across pure and variant histologies in patients with advanced urothelial carcinoma, with the exception of those with a neuroendocrine variant.

Pembrolizumab has been granted a second tumor-agnostic FDA indication, this one for patients with solid tumors with a high tumor mutational burden.

Neoadjuvant pembrolizumab plus chemotherapy achieved a high rate of pathologic downstaging to noninvasive disease and was associated with a high radical cystectomy rate in cisplatin-eligible patients with urothelial cancer.

MRI-guided laser focal therapy showed a better safety profile than standard treatments for patients with localized prostate cancer.

The regimen of apalutamide, abiraterone acetate, and prednisone showed viability as an ADT-free alternative in patients with advanced prostate cancer with noncastrate testosterone levels.